Valuation: Clene Inc.

Market Cap 51.31M 45.81M 42.04M 38.24M 71.7M 4.86B 73.13M 502M 202M 2.56B 193M 188M 8.1B P/E 2026 *
-1.4x
P/E 2027 * -2.12x
Enterprise Value 46.71M 41.7M 38.27M 34.81M 65.27M 4.42B 66.57M 457M 184M 2.33B 175M 172M 7.37B EV / Sales 2026 *
187x
EV / Sales 2027 * 2.28x
Free-Float
83.46%
Yield 2026 *
-
Yield 2027 * -
1 day-5.74%
1 week-5.99%
Current month-5.74%
1 month-11.52%
3 months-28.02%
6 months-41.21%
Current year-38.50%
1 week 3.6
Extreme 3.605
4.05
1 month 3.02
Extreme 3.0152
4.11
Current year 3.02
Extreme 3.0152
8.67
1 year 3.02
Extreme 3.0152
11.98
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
122.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26 Free

Chief Executive Officer

15,244 0.1186%
16/09/26 Free

Chairman

434,451 3.3813%
16/09/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-5.74%-5.99%-71.12%-53.46% 51.31M
-2.37%-5.03%+39.49%+62.39% 62.23B
-0.08%+0.08%+10.37%+68.26% 54.92B
-0.25%+1.51%+19.70%+96.11% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
+0.12%+23.72%+98.87%+83.56% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
Average -1.37%+3.25%+32.53%+156.47% 38.62B
Weighted average by Cap. -1.10%+2.74%+44.58%+162.45%

Financials

2026 *2027 *
Net sales 249K 223K 204K 186K 348K 23.61M 355K 2.44M 984K 12.46M 936K 916K 39.36M 23.27M 20.77M 19.06M 17.34M 32.51M 2.2B 33.16M 228M 91.77M 1.16B 87.32M 85.46M 3.67B
Net income -34.49M -30.79M -28.26M -25.7M -48.19M -3.27B -49.15M -337M -136M -1.72B -129M -127M -5.44B -31M -27.68M -25.4M -23.1M -43.31M -2.93B -44.18M -303M -122M -1.55B -116M -114M -4.89B
Net Debt -4.6M -4.11M -3.77M -3.43M -6.43M -435M -6.56M -45.01M -18.14M -230M -17.26M -16.9M -726M 1.8M 1.61M 1.47M 1.34M 2.52M 170M 2.57M 17.61M 7.1M 89.94M 6.76M 6.61M 284M
Projected Income Statement - Annual - Clene Inc.
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
02/11/26 $3.610 -5.74% 54,014
30/10/26 $3.830 -1.79% 47,273
29/10/26 $3.900 -3.23% 34,254
28/10/26 $4.030 +1.51% 44,069
27/10/26 $3.970 +3.39% 31,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Clene Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.610USD
Average target price
32.20USD
Spread / Average Target
+791.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Clene Inc.
  1. Stock Market
  2. Stocks
  3. CLNN Stock